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Pulmonary embolism (PE) is considered 
to be a major cause of mortality, morbidity 
and hospitalization in Europe. Haemody-
namic benefits of thrombolysis in patients 
with shock and hypotension are undeni-
able, but the role of thrombolytic therapy 
on the outcome of haemodynamically sta-
ble patients still remains controversial.
This is a retrospective analysis of patients 
with acute PE treated with thrombolytic 
therapy in medical intensive care unit 
(ICU), University Hospital Sveti Duh, be-
tween March 2014 and April 2015 .
Twenty two of 75 (29%) patients with PE 
received thrombolytic therapy. The mean 
age of patients was 63 years, 45% were 
male and 55% female. The major symp-
toms were: dyspnea (73%), chest pain 
(18%) and syncope (9%). 27% of patients 
receiving thrombolytic therapy were 
haemodynamically unstable and 73% were 
stable. All patients had an extensive clot 
burden on computed tomographic pul-
monary angiography (CTPA). All haemo-
dynamically stable patients had echocar-
diographic signs of right ventricular (RV) 
dysfunction. Troponin I was positive in all 
haemodynamically unstable patients and 
in 50% of haemodynamically stable pa-
tients. Only one (5%) haemodynamically 
unstable patient died but not because of PE 
or therapy complication. All other patients 
survived and recovered completely. Two 
patients (9%) had major non-intracranial 
bleeding complications, which were suc-
cessfully treated with supportive therapy.
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 INTRODUCTION
Acute pulmonary embolism (PE) is the 
most serious clinical presentation of ve-
nous thromboembolism (VTE). Overall 
annual incidence of VTE is 100-200 per 
100000 inhabitants, and it is the third most 
frequent cardiovascular disease. PE is con-
sidered a major cause of mortality, mor-
bidity and hospitalization in Europe. (1, 2)
VTE can be a consequence of temporary 
or reversible risk factors such as surgery, 
trauma, immobilization, pregnancy, oral 
contraceptive use or hormone replacement 
therapy. VTE can also be ‘unprovoked’ if 
none of the known risk factors are present. 
Antithrombotic prophylaxis significantly 
reduces the risk of perioperative VTE. 
PE may also occur in the absence of any 
known risk factor. (3)
Clinical signs and symptoms of PE are 
non-specific. In most cases PE is suspected 
on the basis of dyspnoea, chest pain, pre-
syncope or syncope and haemoptysis. (4) 
Based on the clinical status at presentation, 
patients are classified in two PE-related 
early mortality risk groups; high-risk be-
ing suspected or confirmed in the presence 
of shock or persistent hypotension and not 
high-risk in their absence. Risk stratifica-
tion based on haemodynamic status is the 
first step in decision making strategies for 
both the diagnostic and therapeutic proce-
dures. (5)
If PE is suspected in patient with shock or 
hypotension and computed tomographic 
pulmonary angiography (CTPA) is avail-
able, it should be done immediately. If 
CTPA is not available echocardiography 
is an alternative diagnostic test. In the case 
PE is suspected in a patient without shock 
or hypotension, the first step is to assess 
clinical probability of PE (Wells or Geneva 
score). If there is high clinical probability 
CTPA should be done. In the case of low 
clinical probability first D-dimer should be 
done and only if it is positive CTPA should 
be performed. (4, 5)
Haemodynamic benefits of thrombolysis 
in PE patients with shock and hypotension 
are undeniable. Thrombolysis restores pul-
monary perfusion more rapidly than anti-
coagulation with unfractionated heparin 
(UFH) alone. The early resolution of pul-
monary obstruction leads to a prompt re-
duction in pulmonary artery pressure and 
resistance, with a concomitant improve-
ment in right ventricular (RV) function. 
(6) The greatest benefit is observed when 
treatment is initiated within 48 hours of 
symptom onset, but thrombolysis can still 
be useful in patients who have had symp-
toms for 6-14 days. (7)
The effect of thrombolytic therapy on the 
outcome of haemodynamically stable pa-
tients who have submassive PE has been 
debated for years and remains controver-
sial. (8, 9) The ongoing controversy is a re-
sult of several factors: the lack of large ran-
domized study, the risk of serious bleeding 
associated with trombolytic therapy and 
the fact that heparin therapy alone can 
improve haemodynamic status gradually. 
(10)
Thrombolytic treatment carries a risk 
of major bleeding, including intracra-
nial haemorrhage. (11) In the category of 
haemodynamically stable patients both the 
risk of bleeding and the benefits of accel-
erated lysis of clot must be taken into ac-
count. Decision making process on thera-
peutic strategy in patients with PE should 
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be done promptly. It should be individual-
ized and both benefits and risks should be 
carefully weighed on a case-by-case basis. 
Patient preferences should also be taken 
into consideration. (10) 
The aim of this study was to analyze char-
acteristics of patients with PE treated with 
thrombolytic therapy in our ICU, the 
bleeding or other complications of the 
therapy and the patient outcome.
MATERIALS AND METHODS
This is a retrospective analysis of patients 
with acute PE treated with recombinant 
tissue type plasminogen activator (tPA) 
alteplase in medical intensive care unit 
(ICU), University Hospital Sveti Duh. The 
study was conducted between March 2014 
and April 2015. In that period 22 adult pa-
tients with PE received alteplase (Actylise, 
Boehringer Ingelheim Pharma GmbH & 
Co.). In all patients the diagnosis was con-
firmed with CTPA. Written informed con-
sent was obtained from all patients. Total 
dose of 100 mg of alteplase was given via 
peripheral intravenous catheter as 2h in-
fusion. According to our protocol, which 
arises from previous vast experience with 
streptokinase, during alteplase infusion 
other anticoagulant agents were discontin-
ued. After the end of alteplase, unfraction-
ated heparin (UFH) was started in con-
tinuous infusion without the bolus dose. 
Further titration of UFH therapy was done 
on the basis of Raschke normogram. After 
a few days and clinical improvement, low 
molecular weight heparin (LMWH) was 
administered together with warfarin. 
We reviewed medical charts on patients’ 
characteristics (age, gender, symptoms of 
disease, risk factors), haemodynamic sta-
tus (blood pressure and heart rate), CTPA 
finding and signs of right ventricular dys-
function (troponin I, echocardiography, 
electrocardiography). Pulmonary embo-
lism severity index (PESI) and early mor-
tality risk stratification was assessed for all 
patients. Evaluation of bleeding or other 
complications and patient outcome was 
done.
RESULTS
In the analysed period 75 patients (10% 
of all hospitalized patients) with CTPA 
confirmed PE were hospitalized in the 
medical ICU. 22 (29%) of them received 
thrombolytic therapy. Table 1 shows pa-
tients’ characteristics. The mean age of 
patients treated with thrombolytic therapy 
was 63 years (range from 25 to 80 years), 
45% were male, and 55% female. The 
major symptom in 73% of patients was 
dyspnoea, in 18% chest pain, and in 9% 
syncope. Two major risk factors for PE 
were malignancy (37%) and immobiliza-
tion (18%). 27% of patients receiving al-
teplase had signs of hemodynamic insta-
bility while 73% were hemodynamically 
stable. All haemodynamically stable pa-
tients had echocardiographic signs of RV 
dysfunction. Considering ECG changes 
sinus tachycardia was most frequent ECG 
abnormality (64%). Other abnormalities 
observed were: T wave inversion in V1-V3 
(55%), S1Q3T3 pattern (55%), right bun-
dle branch block (45%). Only one patient 
had normal ECG. Troponin I was positive 
in all haemodynamically unstable patients, 
while in haemodynamically stable group 
it was positive in 50% of patients. Overall 
troponin I was positive in 58% of patients 
treated with thrombolytic therapy. All 
patients had an extensive clot burden on 
CTPA. Early mortality risk stratification 
was assessed for all patients. 27% were in 
the high risk group, 55% in the interme-
diate-high risk group, and 18% in the in-
termediate-low risk group. By using PESI 
criteria the majority of patients (73%) were 
categorized in class V (very high mortal-
ity risk). Only one haemodynamically 
unstable patient (5%) died, not because 
of PE or therapy complication, but from 
septic complication which occurred on the 
fourteenth day of hospitalization. All other 
patients survived and were discharged in 
improved condition. Two patients (9%) 
had a major bleeding complication, which 
was successfully treated with supportive 
therapy with no need for invasive or sur-
gical interventions. One patient from the 
intermediate-high risk group had skin and 
soft tissue bleeding and a second one who 
was haemodynamically unstable bled from 
puncture site of central vein catheter. Both 
patients recovered completely. There was 
no intracranial bleeding. 
Table 1. Demographic and clinical patient 
data
N=22






   Dyspnea 73%
   Chest pain 18%
   Syncope 9%
Early risk mortality 
score
   High 27%
   Intermediate-high 55%
   Intermediate-low 18%
   low 0%
SPESI
   Class I 0%
   Class II 18%
   Class III 0%
   Class IV 9%




Positive troponin I 58%
ECG abnormality
   Tachycardia 64%
   T vawe inversion in 
V1-V3
55%
   S1Q3T3 pattern 55%




Bleeding complications 2 (9%)
RV – right ventricle, SPESI –simplified 
pulmonary embolism severity index
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DISCUSSION 
Thrombolysis is an established treatment 
for patients with acute massive PE and 
haemodynamic instability. A review of 
randomized trials (12) and a recent epi-
demiological report (13) indicated that 
thrombolysis is associated with a reduc-
tion in mortality or recurrent PE in high-
risk patients. 
In contrast, the effect of thrombolytic ther-
apy on the outcome of haemodynamically 
stable patients has been debated for many 
years and is still controversial. Situations in 
which clinicians contemplate thrombolytic 
therapy are: RV dysfunction, extensive 
clot burden, cardiopulmonal resuscita-
tion, severe hypoxemia and free-floating 
right atrial or ventricular thrombus. In a 
randomized comparison of heparin vs. al-
teplase in 256 normotensive patients with 
acute PE and evidence of RV dysfunction 
or pulmonary hypertension, thrombolytic 
treatment improved the clinical course of 
patients and prevented further haemody-
namic deterioration and the need for es-
calation to emergency treatment without 
affecting mortality. (10)
More recently, the Pulmonary Embolism 
Thrombolysis (PEITHO) trial was pub-
lished that compared tenecteplase plus 
heparin with placebo plus heparin in 1006 
patients with acute PE who were normo-
tensive and had evidence of RV dysfunc-
tion. (14) The all-cause death or haemo-
dynamic decompensation/collapse was 
significantly reduced with tenecteplase. 
In another randomized study comparing 
LMWH alone vs. LMWH plus an intrave-
nous bolus of tenecteplase in intermediate-
risk PE, patients treated with tenecteplase 
had fewer adverse outcomes, better func-
tional capacity, and greater quality of life. 
(15) 
Thrombolytic treatment carries a risk of 
major bleeding, including intracranial 
haemorrhage. Analysis of pooled data 
from trials using various thrombolytic 
agents and regimens reported intracranial 
bleeding rates between 1.9% and 2.2%. (11, 
16) Increasing age and the presence of co-
morbidities have been associated with a 
higher risk of bleeding complications. (17) 
The PEITHO trial showed a 2% incidence 
of haemorrhagic stroke after thrombolytic 
treatment with tenecteplase (versus 0.2% 
in the placebo arm) in patients with inter-
mediate-high-risk PE. (14)
The results from our study showed that 
thrombolytic therapy was frequently used 
in patients with acute PE. The majority 
of PE patients treated with thrombolytic 
therapy were haemodynamically stable 
and in the intermediate-high risk group. 
The decision to administer alteplase was 
conducted on a case-by-case basis after a 
thorough assessment of benefits and risks 
of thrombolytic therapy. Patient’s prefer-
ences were also taken into consideration. 
Two major factors that contributed to 
the decision to administer alteplase were 
the echocardiographic signs of RV dys-
function and an extensive clot burden on 
CTPA as signs of potential haemodynamic 
destabilization. All haemodinamically sta-
ble patients survived and recovered com-
pletely. Overall none of the patients had in-
tracranial bleeding, and only two patients 
had other bleeding complications, which 
were resolved completely without the need 
for surgical or invasive interventions. Al-
though this study was done on a small 
population, we have positive experience 
with thrombolytic therapy in haemody-
namically stable patients with PE with no 
intracranial bleeding complications so far. 
Further investigations on more patients are 
needed to determine exact recommenda-
tions for the use of thrombolytic therapy in 
haemodynamically stable patients with PE. 
CONCLUSION 
There are still controversies regarding the 
use of thrombolytic therapy in haemody-
namically stable patients with PE. Treat-
ment should be determined on a case-by-
case basis after a thorough assessment of 
benefits and risks of thrombolytic therapy. 
When benefits outweigh the risks, throm-
bolytic therapy can be a life-saving proce-
dure.
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